Le Lézard
Classified in: Health
Subjects: CALENDAR OF EVENTS, HEALTH

The IASLC 19th World Conference on Lung Cancer Arrives in Toronto, Canada


DENVER, Aug. 21, 2018 (GLOBE NEWSWIRE) --

What: The International Association for the Study of Lung Cancer (IASLC) presents the IASLC 19th World Conference on Lung Cancer (WCLC) on September 23-26, 2018, in Toronto, Canada. The WCLC is the world's largest meeting dedicated solely to lung cancer and other thoracic malignancies, and is expected to convene over 7,000 researchers, physicians, specialists, patients, advocates and industry members from around the world.

The WCLC's scientific program features a line-up of global leaders in the field. Presentations focus on cutting-edge science, including the latest breakthroughs in targeted therapies and immunotherapies; advances in screening, early detection and staging; prevention and smoking cessation efforts; patient advocacy initiatives; and much more. Collaboration across disciplines and borders is a meeting highlight. The WCLC's scientific program is available to review online.

When and Where: September 23-26, 2018, Metro Toronto Convention Centre North Building, 255 Front Street West, Toronto, Ontario, M5V 2W6, Canada

Who:  Surgeons, medical oncologists, radiation oncologists, pulmonologists, radiologists, pathologists, epidemiologists, basic research scientists, nurses, allied health professionals, advocates, industry representatives and media partners will gather to share findings and to further progress.

More information: Visit the conference's official website for more information or to register.

About the WCLC:
The World Conference on Lung Cancer (WCLC) is the world's largest meeting dedicated solely to lung cancer and other thoracic malignancies, attracting over 7,000 researchers, physicians and specialists from more than 100 countries. The conference will cover a wide range of disciplines and unveil research studies and clinical trial results. For more information, visit http://wclc2018.iaslc.org/. Follow the conference on social media with: #WCLC2018.

About the IASLC:
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated solely to the study of lung cancer and other thoracic malignancies. Founded in 1974, the association's membership includes more than 7,500 lung cancer specialists across all disciplines in over 100 countries, forming a global network working together to conquer lung and thoracic cancers worldwide. The association also publishes the Journal of Thoracic Oncology, the primary educational and informational publication for topics relevant to the prevention, detection, diagnosis and treatment of all thoracic malignancies. Visit www.iaslc.org for more information. You can also follow the IASLC on Twitter, Facebook, LinkedIn and Instagram.

Contact: Becky Bunn, MSc
IASLC Public Relations Manager
[email protected]  | 720-325-2946  

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/5f8c0583-657a-48a2-9d8b-0b3bd7897a6c


These press releases may also interest you

at 16:42
Grifols, S.A. ("Grifols") (MCE: GRF, MCE: GRF.P, NASDAQ: GRFS), a global healthcare company and leading manufacturer of plasma-derived medicines, today announces the filing of its Annual Report on Form 20-F for the fiscal year ended December 31,...

at 16:27
Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  On Thursday, the FDA posted a safety communication to inform the public and healthcare providers that the agency has required and...

at 16:19
Unifor expects to achieve the wage increases and benefit improvements awarded to Ontario OCHU-CUPE and SEIU Healthcare members by Arbitrator William Kaplan in a recent decision....

at 16:10
Acadia Pharmaceuticals Inc. today announced that on April 10, 2024, the Compensation Committee of Acadia's Board of Directors (the "Committee") granted inducement awards consisting of non-qualified stock options to purchase 21,659 shares of common...

at 16:10
Calidi Biotherapeutics, Inc. , a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the closing of its previously announced public offering of 15,197,500 shares of common stock (or pre-funded...

at 15:55
Valley Mountain Regional Center ("VMRC") experienced a data security incident that involved personal and / or protected health information belonging to certain current and former patients and has provided notice of this incident to impacted...



News published on and distributed by: